Horvath, Augusta and Rogers, Lisa and Pollakis, Georgios and Baranov, Olga and Pieroth, Nora and Joseph, Sarah and Chachage, Mkunde and Heitzer, Asli and Maganga, Lucas and Msafiri, Frank and Joachim, Agricola and Viegas, Edna and Eller, Leigh-Anne and Kibuuka, Hannah and Rerks-Ngarm, Supachai and Pitisuttithum, Punnee and Nitayapan, Sorachai and Dhitavat, Jittima and Premsri, Nakorn and Fidler, Sarah and Shattock, Robin J. J. and Robb, Merlin Lee and Weber, Jonathan and McCormack, Sheena and Munseri, Patricia Jane and Lyamuya, Eligius and Nilsson, Charlotta and Kroidl, Arne and Hoelscher, Michael and Wagner, Ralf and Geldmacher, Christof and Held, Kathrin (2023) Systematic comparison of HIV-1 Envelope-specific IgG responses induced by different vaccination regimens: Can we steer IgG recognition towards regions of viral vulnerability? FRONTIERS IN IMMUNOLOGY, 13: 1075606. ISSN 1664-3224,
Full text not available from this repository. (Request a copy)Abstract
Immunogens and vaccination regimens can influence patterns of immune-epitope recognition, steering them towards or away from epitopes of potential viral vulnerability. HIV-1 envelope (Env)-specific antibodies targeting variable region 2 (V2) or 3 (V3) correlated with protection during the RV144 trial, however, it was suggested that the immunodominant V3 region might divert antibody responses away from other relevant sites. We mapped IgG responses against linear Env epitopes in five clinical HIV vaccine trials, revealing a specific pattern of Env targeting for each regimen. Notable V2 responses were only induced in trials administering CRF01_AE based immunogens, but targeting of V3 was seen in all trials, with the soluble, trimeric CN54gp140 protein eliciting robust V3 recognition. Strong V3 targeting was linked to greater overall response, increased number of total recognised antigenic regions, and where present, stronger V2 recognition. Hence, strong induction of V3-specific antibodies did not negatively impact the targeting of other linear epitopes in this study, suggesting that the induction of antibodies against V3 and other regions of potential viral vulnerability need not be necessarily mutually exclusive.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | IMMUNOGENICITY EVALUATION; MONOCLONAL-ANTIBODIES; GLYCOPROTEIN GP120; IMMUNE-RESPONSE; PHASE-1 SAFETY; EFFICACY TRIAL; ALVAC-HIV; RECOMBINANT; INFECTION; BROAD; HIV; CN54rgp140 vaccine; envelope-specific antibodies; immunogen sequence; V3-antibodies; V2-antibodies; linear peptide array; vaccine |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Medizinische Mikrobiologie und Hygiene |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 23 Mar 2024 12:14 |
| Last Modified: | 23 Mar 2024 12:14 |
| URI: | https://pred.uni-regensburg.de/id/eprint/60445 |
Actions (login required)
 |
View Item |
